Pediatric ovarian germ cell tumor
disease diseaseOn this page
Also known as childhood ovarian germ cell neoplasmchildhood ovarian germ cell tumorchildhood ovarian germ cell tumourovarian germ cell tumorovarian germ cell tumor of childhoodovarian germ cell tumourovarian germ cell tumour of childhoodpediatric ovarian germ cell neoplasm
Summary
Pediatric ovarian germ cell tumor (MONDO:0003760) is a cancer (an umbrella term covering 5 Mondo subtypes) and 44 clinical trials. Top therapeutic interventions include metformin, bleomycin sulfate, and cisplatin. A subtype of childhood germ cell tumor — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Umbrella term: 5 Mondo subtypes
- Clinical trials: 44
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | pediatric ovarian germ cell tumor |
| Mondo ID | MONDO:0003760 |
| DOID | DOID:6084 |
| NCIT | C8588 |
| UMLS | C0796664 |
| MedGen | 162990 |
| GARD | 0023655 |
| Is cancer (heuristic) | yes |
Also known as: childhood ovarian germ cell neoplasm · childhood ovarian germ cell tumor · childhood ovarian germ cell tumour · ovarian germ cell tumor · ovarian germ cell tumor of childhood · ovarian germ cell tumour · ovarian germ cell tumour of childhood · pediatric ovarian germ cell neoplasm · pediatric ovarian germ cell tumor
Disease family
This is a subtype of childhood germ cell tumor. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › germ cell tumor › childhood germ cell tumor › pediatric ovarian germ cell tumor
Related subtypes (3): childhood central nervous system germ cell tumor, malignant childhood germ cell neoplasm, childhood gonadal germ cell tumor
Subtypes (5): childhood ovarian yolk sac tumor, childhood teratoma of the ovary, pediatric ovarian dysgerminoma, childhood ovarian embryonal carcinoma, childhood choriocarcinoma of the ovary
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 44.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 15 |
| PHASE1 | 15 |
| Not specified | 12 |
| PHASE3 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00053352 | PHASE3 | COMPLETED | Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors |
| NCT02834013 | PHASE2 | ACTIVE_NOT_RECRUITING | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors |
| NCT04804007 | PHASE2 | RECRUITING | Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT |
| NCT04876456 | PHASE2 | ACTIVE_NOT_RECRUITING | A Phase II Trial of Cabozantinib With Patients With Refractory GCTs |
| NCT05500391 | PHASE2 | RECRUITING | Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring |
| NCT00042952 | PHASE2 | TERMINATED | Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer |
| NCT00467051 | PHASE2 | COMPLETED | Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors |
| NCT00795769 | PHASE2 | COMPLETED | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant |
| NCT00957905 | PHASE2 | COMPLETED | Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors |
| NCT01037790 | PHASE2 | COMPLETED | Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer |
| NCT01079832 | PHASE2 | COMPLETED | Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies |
| NCT01159067 | PHASE2 | TERMINATED | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload |
| NCT01764802 | PHASE2 | COMPLETED | Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer |
| NCT01808534 | PHASE2 | TERMINATED | Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors |
| NCT02122185 | PHASE2 | COMPLETED | Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| NCT02283658 | PHASE2 | COMPLETED | Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer |
| NCT06276491 | PHASE1 | RECRUITING | Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors |
| NCT00031681 | PHASE1 | COMPLETED | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) |
| NCT00060372 | PHASE1 | COMPLETED | Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer |
| NCT00228358 | PHASE1 | COMPLETED | Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient’s Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine |
| NCT00408655 | PHASE1 | COMPLETED | Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors |
| NCT00436254 | PHASE1 | COMPLETED | Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer |
| NCT00638898 | PHASE1 | COMPLETED | Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor |
| NCT01131234 | PHASE1 | COMPLETED | Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors |
| NCT01155258 | PHASE1 | COMPLETED | Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors |
| NCT01233505 | PHASE1 | TERMINATED | Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors |
| NCT01322802 | PHASE1 | COMPLETED | Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian Cancer |
| NCT01484015 | PHASE1 | COMPLETED | Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia |
| NCT01494012 | PHASE1 | TERMINATED | Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer |
| NCT01652794 | PHASE1 | COMPLETED | Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer |
| NCT02050009 | PHASE1 | WITHDRAWN | Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| NCT02013492 | EARLY_PHASE1 | COMPLETED | Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery |
| NCT01696994 | Not specified | ACTIVE_NOT_RECRUITING | Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial) |
| NCT00087191 | Not specified | TERMINATED | EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer |
| NCT00408681 | Not specified | COMPLETED | Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant |
| NCT00897442 | Not specified | COMPLETED | Collecting Tumor Samples From Patients With Gynecological Tumors |
| NCT01080521 | Not specified | COMPLETED | Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy |
| NCT01126346 | Not specified | COMPLETED | Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC) |
| NCT01558778 | Not specified | WITHDRAWN | Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant |
| NCT01764789 | Not specified | COMPLETED | Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| METFORMIN | 4 | 2 |
| BLEOMYCIN SULFATE | 4 | 1 |
| CISPLATIN | 4 | 1 |
| DEFERASIROX | 4 | 1 |
| DENILEUKIN DIFTITOX | 4 | 1 |
| IMATINIB | 4 | 1 |
| PALBOCICLIB | 4 | 1 |
| VELIPARIB | 3 | 2 |
| CEDIRANIB MALEATE | 3 | 1 |
| PALIFOSFAMIDE | 3 | 1 |
| ALVOCIDIB HYDROCHLORIDE | 2 | 1 |
| UCN-01 | 2 | 1 |
| CHEMBL1236539 | 0 | 1 |